Synapse - Works

Results (5608)

Surgical outcomes and genomic insights of nonclear cell renal cell carcinoma with synchronous and metachronous nodal disease

Journal Article

Eismann, L.; Zucker, M.; Dawidek, M. T.; Reese, S. W.; Calderon, L. P.; Aulitzky, A.; Stief, C. G.; Coleman, J. A.; Kotecha, R. R.; Carlo, M.; more...
Urology Practice (2024)

Fulltext@MSK | Save

Characterising the contribution of rare protein-coding variants to prostate cancer risk and severity in 36,866 cases

Meeting Abstract

Mitchell, J.; Camacho, N.; Shea, P. R.; Stopsack, K.; Joseph, V.; Burren, O.; Penney, K.; Berchuck, J.; Wang, Q. L.; Goldstein, D.; more...
European Journal of Human Genetics (2024)

Fulltext@MSK | Save

Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression

Meeting Abstract

Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution

Meeting Abstract

Apolo, A. B.; Ballman, K.; Sonpavde, G. P.; Berg, S.; Kim, W.; Parikh, R.; Teo, M. Y.; Sweis, R. F.; Geynisman, D.; Grivas, P.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC)

Meeting Abstract

Rosenberg, J. E.; Petrylak, D. P.; Flaig, T.; Hoimes, C. J.; Gupta, S.; O'Donnell, P. H.; Mar, N.; Friedlander, T.; Tagawa, S. T.; Bilen, M. A.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)

Meeting Abstract

Powles, T. B.; van der Heijden, M. S.; Gupta, S.; Perez Valderrama, B.; Galsky, M. D.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Maroto Rey, J. P.; Vulsteke, C.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2- expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C

Meeting Abstract

Galsky, M. D.; Koshkin, V. S.; Campbell, M. T.; Drakaki, A.; Bowman, I.; Rose, A. A. N.; Brown, J. R.; Aragon-Ching, J. B.; Gadde, S.; Harandi, A.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)

Meeting Abstract

Venugopal, B.; Choueiri, T. K.; Penkov, K. D.; Albiges, L.; Uemura, H.; Larkin, J.; Tomita, Y.; Wang, J.; Hoffman, J.; Gerhold-Ay, A.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)

Meeting Abstract

Rathkopf, D.; Dallos, M.; Stein, M.; Spina, C. S.; Deutsch, I.; Nguyen, C.; Okada, A.; Lloyd, M.; Manarite, J.; McBride, S.
Annals of Oncology (2024)

Fulltext@MSK | Save

Validation of automated bone scan index as a progression endpoint in two phase III studies of metastatic castration resistant prostate cancer (mCRPC) patients

Meeting Abstract

Knezevic, A.; Heller, G.; Sjöstrand, K.; Anand, A.; Borzillo, G.; Larson, S.; Morris, M. J.
Annals of Oncology (2024)

Fulltext@MSK | Save